Therapeutic targeting of this receptor in OAC warrants further investigation, particularly given that in-vivo in pancreatic cancer xenografts, primary tumour volume and lung metastasis were increased by LIFR silencing and tumour volume and metastasis were reduced and inhibited respectively when LIFR was overexpressed in primary implanted pancreatic cancer cells [38]. The gene discussed is LIFR; the disease is pancreatic neoplasm.